AI in Drug Discovery Startup Funding 2025-2026

What are all the funding deals in the AI in drug discovery market from July 2025 to June 2026?

The table below lists every disclosed equity round raised by pure-play AI in drug discovery companies between July 2025 and June 2026. We count as “pure-play” AI in drug discovery companies those whose core activity materially supports target identification, hit and lead generation, lead optimization, de novo design, repurposing, or preclinical prediction before human trials.

Each row shows the company, what it does, its category, the deal date, the funding stage, the round size, the region, the main investors disclosed in the provided dataset, and the announcement source. For a wider view of how AI-enabled discovery fits inside the broader pharmaceutical innovation stack, we cover it in our AI in Drug Discovery market report.

How active has fundraising been in the AI in drug discovery market?

As of June 2026, fundraising in the AI in drug discovery market has been active over the past 12 months. The dataset includes 29 disclosed equity rounds and $3.83B raised between July 2025 and June 8, 2026.

Deal flow was not sparse. The market averaged 2.4 disclosed deals per month, with a median of 2.0 deals per month across the period.

The dollar flow looks much larger than the typical month. Average monthly capital was $319.5M, but the median month raised only $93.2M, which shows how much the total depends on a few exceptional rounds.

April 2026 had the highest deal count, with 5 disclosed rounds and $86.3M raised. March 2026 and May 2026 had only one deal each, but those months produced $787.0M and $2.1B respectively.

For more context on the companies and categories behind this activity, see our AI in Drug Discovery market report.

How concentrated has fundraising been in the AI in drug discovery market?

As of June 2026, fundraising in the AI in drug discovery market is highly concentrated over the past 12 months. The top deal alone represents 54.8% of total disclosed capital, and the top 3 deals represent 78.7%.

This is not a market where the headline funding total describes the average company. The top 5 deals account for 83.4% of capital, and the top 10 deals account for 91.2%.

Isomorphic Labs is the main reason the market looks so large by dollars. Its $2.1B Series B is bigger than the combined capital raised by every non-megaround in the dataset.

The concentration also appears at category level. De Novo Design captured 90.6% of disclosed capital, even though it represented only 37.9% of deals.

How much of the AI in drug discovery funding signal is driven by outliers?

As of June 2026, most of the AI in drug discovery funding signal is driven by outliers over the past 12 months. The average round size is $132.2M, while the median round size is only $26.0M.

That gap is the simplest way to read the market. A typical financing is closer to a $20M to $30M round, while the market average is pulled upward by Isomorphic Labs, Earendil Labs, Chai Discovery, Iambic Therapeutics, CHARM Therapeutics, and Proxima.

Megarounds above $50M represented 8 of 29 deals, or 27.6% of all disclosed rounds. Those few rounds determined the economic shape of the entire AI in drug discovery market.

Excluding rounds above $50M, total capital falls from $3.83B to $435.1M. That means the market is active beyond the giants, but the dollar narrative is overwhelmingly a mega-platform narrative.

Is the AI in drug discovery market broad with many targets, or narrow with few fundable companies?

As of June 2026, the AI in drug discovery market is broad on formation but narrow on capital allocation over the past 12 months. The dataset includes 29 deals across 28 unique companies, so many companies crossed the disclosed funding threshold.

Only Chai Discovery appears twice in the disclosed period. That means the row-level market is not dominated by repeat raises from the same companies.

The capital story is much narrower. One company accounts for 54.8% of capital, and three companies account for 78.7%, so the funding market is deciding very aggressively which platforms deserve balance sheets.

The category split confirms the same pattern. AI Lead Generation, AI Target Discovery, and Preclinical Prediction AI all produced deals, but De Novo Design absorbed nearly all the capital.

Is AI in drug discovery mostly an early-stage formation market or a late-stage scaling market?

As of June 2026, the AI in drug discovery market is mostly an early-stage formation market by deal count, but a late-stage scaling market by dollars over the past 12 months. Seed plus Series A rounds represented 18 of 29 deals, or 62.1% of activity.

Early-stage capital was much smaller than early-stage activity. Seed plus Series A raised $450.6M, equal to only 11.8% of total disclosed capital.

Series B moved the market by dollars. Series B represented just 5 deals, or 17.2% of activity, but captured $2.39B and 62.3% of all disclosed capital.

Unknown-stage financings were also meaningful. They accounted for 6 deals and $994.5M, reflecting the blurred boundary between biotech rounds, platform financings, and strategic capitalization.

If you want a deeper view of how stages map to investor conviction, we cover this in our market report on AI drug discovery funding.

Which categories attract the most investor attention in AI in drug discovery?

As of June 2026, De Novo Design attracts the most investor attention in the AI in drug discovery market over the past 12 months. It led both by deal count and by capital, with 11 deals and $3.47B raised.

AI Lead Generation ranked second by deal count, with 9 disclosed rounds and $246.0M raised. This shows that investors still fund tools and platforms that help generate hits, leads, and molecules.

AI Target Discovery produced 5 deals but only $56.6M in capital. That suggests target biology remains strategically important, but investors are not yet underwriting it at the same scale as design engines.

Preclinical Prediction AI produced 4 deals and $59.3M raised. The category matters because AI-generated candidates still need toxicity, characterization, and failure prediction, but it remains undercapitalized relative to that gating role.

Which categories attract disproportionately large checks in the AI in drug discovery market?

As of June 2026, De Novo Design attracts disproportionately large checks in the AI in drug discovery market over the past 12 months. The category captured 90.6% of capital from 37.9% of deals, giving it a capital-share-to-deal-share ratio of 2.39.

The median De Novo Design round was $80.0M, far above the market-wide median of $26.0M. The average was $315.7M because the category includes Isomorphic Labs, Earendil Labs, Chai Discovery, Iambic Therapeutics, CHARM Therapeutics, and Proxima.

AI Lead Generation had a much lower ratio at 0.21. It accounted for 31.0% of deals but only 6.4% of dollars, which means the category gets funded often but not usually at platform-scale check sizes.

Preclinical Prediction AI and AI Target Discovery were even more underweighted by capital. Their ratios were 0.11 and 0.09, which confirms that investors are paying more for creation than for filtration or upstream evidence quality.

Which geographies matter most for fundraising in the AI in drug discovery market?

As of June 2026, Europe and North America matter most for fundraising in the AI in drug discovery market over the past 12 months. Together they accounted for 26 of 29 deals and 97.9% of disclosed capital.

Europe led by dollars, with $2.32B raised and 60.4% of total capital. That lead is real in the dataset, but it depends heavily on Isomorphic Labs’ $2.1B Series B.

North America led by deal count, with 16 disclosed rounds and 55.2% of all deals. It raised $1.44B, equal to 37.5% of total capital.

Asia-Pacific was present but smaller. It produced 3 deals and $81.7M, equal to 10.3% of deals and 2.1% of disclosed capital.

For a fuller breakdown of where the strongest company formation is happening, see our AI in Drug Discovery geography analysis.

Is the AI in drug discovery opportunity set broad or concentrated in one hub?

As of June 2026, the AI in drug discovery opportunity set is concentrated in two main hubs over the past 12 months, not one. North America and Europe together hold almost all disclosed capital and most of the deal count.

North America looks like the deepest formation market. Its 16 deals matter because they show repeated company creation and fundraising across several categories, not just one exceptional transaction.

Europe looks like the largest capital market in this sample, but the signal is fragile. Without Isomorphic Labs, North America would dominate both deal count and capital.

Asia-Pacific shows credible technical activity in protein design, peptide discovery, and self-driving labs. But its capital share remains small compared with the US and European mega-platform financings.

Is AI in drug discovery a market of small experiments or scaled financings?

As of June 2026, the AI in drug discovery market is a barbell of small and mid-sized experiments plus a few scaled financings over the past 12 months. Most deals were below $50M, but most dollars were above that level.

The size distribution shows this clearly. There were 3 deals under $5M, 7 deals from $5M to under $20M, 11 deals from $20M to $50M, and 8 deals above $50M.

That means 21 of 29 deals were $50M or below. But once a company cleared the megaround threshold, the check sizes became large enough to dominate every dollar-based metric.

The median round was $26.0M, which is a better read on the middle of the AI in drug discovery market than the $132.2M average. The average mostly describes outlier financings, not the typical disclosed round.

If you want to track which rounds are true scaling events rather than formation checks, explore our full market deck on AI drug discovery.

Is funding in AI in drug discovery driven more by first financings or follow-on rounds?

As of June 2026, funding in the AI in drug discovery market is driven more by follow-on rounds than first financings over the past 12 months. The largest capital allocations generally went to companies with prior proof, syndicates, or platform credibility.

First financings did occur across the dataset. DaltonTx, Scripta Therapeutics, Proxima, DeepCyte, Helical, 10x Science, and Fathom Therapeutics show that new-company creation remains active.

But most first financings were small compared with the biggest follow-ons. Proxima is the major exception, with an $80M seed round that immediately placed it among the better-capitalized companies in the sample.

This pattern matters because it separates formation from conviction. Investors are still starting new AI discovery companies, but they are concentrating the largest checks on platforms that already look more validated.

Who are the investors that appear the most in AI in drug discovery fundraising?

As of June 2026, a small group of repeat investors appears most often in AI in drug discovery fundraising over the past 12 months. Their repetition matters because it shows where specialist capital is building conviction.

DCVC appears in Chai Discovery, Proxima, and Relation Therapeutics. AIX Ventures appears in Tahoe Therapeutics and Proxima, while Yosemite appears in Chai Discovery and Proxima.

Menlo Ventures / Anthology Fund appears in Chai Discovery and Medra. Mubadala Capital / Mubadala Ventures appears in Tahoe Therapeutics and Iambic Therapeutics, while Catalio appears in Iambic Therapeutics and Medra.

Strategic and deep life-science investors also repeat. NVIDIA / NVentures appears in CHARM Therapeutics and Relation Therapeutics, Alexandria appears in Iambic Therapeutics and Fathom Therapeutics, and Dimension appears in Tamarind Bio and Earendil Labs.

One caveat is important: round announcements usually disclose participation, not individual check sizes. For more context on investor patterns and category conviction, see our deeper analysis of the AI in drug discovery market.

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living "market pitch" documents for emerging markets: AI, synthetic biology, new proteins, and more. Instead of outdated PDFs or hallucinated LLM answers, our clients get a clean, visual, always-updated view of what's really happening: key players, deals, regulations, and signals that matter. Learn more about us.